2025 ICD-10-CM code C92.00
(Active) Effective Date: N/A Neoplasms - Malignant neoplasms of lymphoid, hematopoietic and related tissue 2 (Neoplasms) Feed
Acute myeloblastic leukemia (AML) that has been treated, but signs and symptoms remain.
Medical necessity is established by the diagnosis of AML and the persistence of disease after treatment.Continued monitoring and further treatment are required to manage the condition and prevent progression.
The provider performs a thorough evaluation, including patient history, physical exam (looking for enlarged lymph nodes, bruising, or bleeding), and laboratory tests (CBC, peripheral smear, blood chemistries, coagulation studies).A bone marrow biopsy or aspiration is crucial for diagnosis.Further tests like lumbar puncture, cytologic analysis, flow cytometry, PCR, FISH, genetic analysis, and imaging studies (CT, MRI, PET, ultrasound) may be necessary for staging and subtyping the disease.Treatment includes chemotherapy, targeted therapy, stem cell transplant, radiation therapy, or surgery.
In simple words: AML is a type of blood cancer where the bone marrow makes too many abnormal white blood cells.This code is specifically used when AML is still present even after treatment.
Acute myeloblastic leukemia (AML) occurs when large number of myeloblasts (immature blood cells in the bone marrow) enter the blood stream or when the bone marrow produces abnormal white blood cells which then overwhelm or replace healthy blood cells and keep the blood from functioning as it should. It is most common form of myeloid leukemia, which can worsen if not treated. Risk factors include chemotherapy, smoking, and exposure to radiation.This code is used for AML that has been treated, but signs and symptoms remain.
Example 1: A 65-year-old patient with AML underwent induction chemotherapy but still exhibits fatigue, low blood counts, and bone pain., A 30-year-old patient completed AML treatment but follow-up bone marrow biopsy shows persistent presence of myeloblasts, although at less than 5%., A patient with AML post-chemotherapy has persistent symptoms such as easy bruising, recurrent infections, and anemia despite achieving partial remission.
Documentation should include complete blood counts, bone marrow biopsy/aspiration results, cytogenetics and molecular marker studies, imaging reports if applicable, and a detailed description of the patient's clinical status including signs and symptoms.
- Specialties:Hematology, Oncology
- Place of Service:Inpatient Hospital, On Campus-Outpatient Hospital, Office